Expression of Peroxisome Proliferato Activated Receptor gamma in Prostatic Adenocarcinoma.
10.3346/jkms.2015.30.5.533
- Author:
Hyung Kyu PARK
1
;
Hyunkyung KIM
;
Hyeong Gon KIM
;
Young Mee CHO
;
Woon Yong JUNG
;
Hye Seung HAN
;
Tae Sook HWANG
;
Ghee Young KWON
;
So Dug LIM
Author Information
1. Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea. sdlim@kuh.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Prostatic Neoplasms;
PPAR gamma;
Immunohistochemistry;
Real-Time Polymerase Chain Reaction
- MeSH:
Adenocarcinoma/metabolism/*pathology;
Adult;
Aged;
Aged, 80 and over;
*Gene Expression Regulation, Neoplastic;
Humans;
Immunohistochemistry;
Male;
Middle Aged;
Neoplasm Staging;
PPAR gamma/*genetics/*metabolism;
Prostate/pathology;
Prostatectomy;
Prostatic Neoplasms/metabolism/*pathology;
RNA, Messenger/metabolism;
Real-Time Polymerase Chain Reaction;
Tissue Array Analysis
- From:Journal of Korean Medical Science
2015;30(5):533-541
- CountryRepublic of Korea
- Language:English
-
Abstract:
Peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor has been investigated as the target for cancer treatment as well as metabolic disorders. Recent studies have demonstrated that PPAR-gamma ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects. The aim of this study was to validate PPAR-gamma expression in malignant and benign prostate tissues by immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). A total of 730 prostatic adenocarcinomas (PCAs) including 63 whole sections from radical prostatectomy specimens and tissue microarrays containing 667 PCAs were subject to immunostaining for two PPAR-gamma antibodies. Twenty-five benign prostate tissues and PCAs were selected for investigating mRNA expression by quantitative real-time PCR. 10.7% of PCAs (78/730) showed cytoplasmic immunoreactivity of PPAR-gamma and no nuclear immunoreactivity was noted in PCAs. Most benign prostatic glands showed negative immunoreactivity of PPAR-gamma except for variable weak cytoplasmic staining in some glands. Nuclear immunoreactivity of PPAR-gamma was noted some central zone and verumontanum mucosal epithelium. The constitutive PPAR-gamma mRNA showed significantly lower level in PCAs compared to that in the benign tissues. There was no difference of PPAR-gamma mRNA expression between low (< or =7) and high (>7) Gleason score groups. There was no association of PPAR-gamma mRNA level or cytoplasmic immunostaining with Gleason grade or pathologic stage. Our study supported the evidence of extra-nuclear localization and nongenomic actions of PPAR-gamma. Further studies are needed to assess the functional role of PPAR-gamma and to validate its therapeutic implication in prostate cancer.
